CytomX Therapeutics (CTMX) Research & Development (2014 - 2026)

CytomX Therapeutics has reported Research & Development for 13 years, with the latest figure at $19.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 1.96% year-over-year to $19.2 million; the trailing twelve-month figure through Mar 2026 stood at $69.1 million (down 13.84% YoY), and the FY2025 full-year result was $68.7 million, down 17.57% from the prior year.
• Research & Development for Q1 2026 stood at $19.2 million, down from $21.2 million in the prior quarter.
• The five-year high for Research & Development was $31.2 million in Q2 2022, with the low at $13.3 million in Q2 2025.
• Historically, Research & Development has averaged $21.2 million across 5 years, with a median of $20.7 million in 2023.
• The largest YoY upside for Research & Development was 43.58% in 2025 against a maximum downside of 47.08% in 2025.
• CytomX Therapeutics' Research & Development stood at $19.6 million in 2022, then declined by 0.91% to $19.4 million in 2023, then retreated by 23.71% to $14.8 million in 2024, then surged by 43.58% to $21.2 million in 2025, then retreated by 9.4% to $19.2 million in 2026.
• The last three Research & Development figures came in at $19.2 million (Q1 2026), $21.2 million (Q4 2025), and $15.3 million (Q3 2025), per Business Quant data.